Terapias biológicas en el lupus eritematoso sistémico / Biological therapies in systemic lupus erythematosus
Rev. méd. Chile
;
138(7): 881-887, July 2010.
Artículo
en Español
| LILACS
| ID: lil-567594
ABSTRACT
The immunosuppressive agents used in patients with systemic lupus erythematosus (SLE) have signifcantly improved prognosis. However, it is necessary to develop more specifc immunosuppressive treatments with less toxicity. Better understanding of the mechanisms involved in the loss of tolerance in autoimmune diseases has contributed to the development of potential new treatments called biologic therapies. The targets of these biological therapies are directed toward the B cell depletion, interference in the co-stimulation signals and the blockade of cytokines. Therapies using anti-CD20 monoclonal antibodies have shown satisfactory results especially in patients with SLE refractory to conventional treatment. The biological therapies provide encouraging results that represent a possible option in the treatment of refractory patients as well as a potential therapy in the future management of SLE.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Terapia Biológica
/
Lupus Eritematoso Sistémico
/
Anticuerpos Monoclonales
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS